Rise and shine, everyone, another busy day is on the way. And the Pharmalot campus is no exception. Our shortest person has left for the local schoolhouse, the other short one is gearing up for a new round of gainful employment, and our official mascot is breathing heavily nearby. All of which means we are, more or less, left to our own devices. Scary thought, yes? Well, take heart. We have faithfully assembled the latest menu of tidbits for you to peruse. Hope your day is smashing and, as always, do keep in touch. …

A U.S. judge rejected efforts by major drug makers, pharmacies, and distributors to dismiss claims that they caused the nation’s opioid crisis, clearing the way for a scheduled landmark trial even as he pushes for a nationwide settlement, Reuters reports. U.S. District Judge Dan Polster, who oversees roughly 2,000 opioid lawsuits by states, counties, and cities, ruled the plaintiffs can try to prove that deceptive marketing of the painkillers caused a harmful, massive increase in supply that pharmacies and distributors did not do enough to stop.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy